At 24 weeks after the end of therapy , sustained virologic responses were achieved in 89 % , 93 % , 91 % , and 86 % of the patients in the groups given the combination of PR and MK-5172 ( 100 , 200 , 400 , or 800 mg ) , respectively , vs 61 % of controls .